Metabolomics study of alcohol-induced liver injury and hepatocellular carcinoma xenografts in mice

Li, Shangfu; Liu, Hongxia; Jin, Ya; Lin, Shuhai; Cai, Zongwei; Jiang, Yuyang

doi:10.1016/j.jchromb.2011.06.018

Cited by 52 publications

(58 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…47 Individual discriminating metabolites associated with autism and controls were selected primarily according to the VIP (> 1.0) values and a statistical test for difference (p < 0.05) between patients wiht autism and controls. While some suggest using a VIP greater than 2 52 as a criterion for selecting an individual metabolite, we chose a VIP greater than 1, similar to other studies, 53,54 in order to analyze more metabolites. Our approach took into account both predicting capability and statistical significance of individual metabolites in association with autism.…”

Section: Data Preprocessing and Analysismentioning

confidence: 99%

Potential serum biomarkers from a metabolomics study of autism

Wang

Liang

Wang

et al. 2016

jpn

104

View full text Add to dashboard Cite

Section: Data Preprocessing and Analysismentioning

confidence: 99%

Potential serum biomarkers from a metabolomics study of autism

Wang

Liang

Wang

et al. 2016

jpn

104

View full text Add to dashboard Cite

“…Disorder of amino acid metabolism are found in some liver diseases at the metabolomics level (23)(24)(25). We defined decreased amounts of valine and isoleucine, glutamine, and glutamate in sera of decompensated HCV-cirrhosis compared to healthy controls.…”

Section: Mitochondrial Pathwaysmentioning

confidence: 99%

Serum Metabolic Profiling of Advanced Cirrhosis Based on HCV

et al. 2017

View full text Add to dashboard Cite

Background: Cirrhosis is recognized by a reduction in hepatocyte proliferation with an increase in fibrous tissue, which may ultimately lead to the development of cancerous nodules. Liver biopsy has remained the gold standard for confirming liver fibrosis stages, but there are not any nonreversible and specific therapeutic targets in advanced cirrhosis. In the present study, we used the NMR method to find potential therapeutic markers in serum of HCV -cirrhotic patients with advanced stage.Methods: A metabolic profiling study was conducted using 2 groups: decompensated HCV-cirrhosis patients (n = 21) and healthy controls (n = 18). 1H nuclear magnetic resonance (NMR) approach was used to obtain the serum metabolic profiles of the samples. The acquired data were processed by the multivariate principal component analysis (PCA) and orthogonal partial least squares discriminant analysis (OPLS-DA). Moreover, metabolic pathways were determined using MetaboAnalyst 3.0.Results: Specifically, 16 metabolites showed alteration between the 2 groups. Compared with healthy controls, a number of metabolites showed increased concentration in serum of decompensated HCV-cirrhosis such as succinic acid, isovaleraldehyde, citrulline, propanal and cinnamaldehyde, while several others were observed in decreased levels in the decompensated HCV-cirrhosis such as valine, glutamine, trimethylamine, lactate, proline, aspartate, lipid, VLDL, isoleucine, fucose, and glutamate. Aminoacyl-tRNA biosynthesis, alanine, aspartate, glutamate metabolism and arginine, and proline metabolism are the most significant pathways associated with advanced HCV-cirrhosis. Conclusions:Metabolomic profiling through NMR can identify the metabolic disturbances in advanced HCV-cirrhosis. Aberrant amino acid biosynthesis may be the hallmark with increasing severity of cirrhosis as well as alterations in energetic metabolism.

show abstract

“…14,15 Over the last few years there has been a rapidly growing number of metabolomic applications aimed at finding biomarkers that could assist diagnosis, provide therapy guidance, and evaluate response to therapy for a particular HCC. [16][17][18] Today, the improved efficiency and accuracy of metabolomic biomarker discovery technologies are turning diagnostics into a clinical reality. 19,20 The future goals for metabolomics are the validation of existing biomarkers, in terms of mechanism and translation to man, together with a focus on characterizing the individual healthcare.…”

mentioning

confidence: 99%

Power of metabolomics in diagnosis and biomarker discovery of hepatocellular carcinoma

2013

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the commonest primary hepatic malignancy and the third most common cause of cancer-related death worldwide. Incidence remains highest in the developing world and is steadily increasing across the developed world. Current diagnostic modalities, of ultrasound and a-fetoprotein, are expensive and lack sensitivity in tumor detection. Because of its asymptomatic nature, HCC is usually diagnosed at late and advanced stages, for which there are no effective therapies. Thus, biomarkers for early detection and molecular targets for treating HCC are urgently needed. Emerging highthroughput metabolomics technologies have been widely applied, aiming at the discovery of candidate biomarkers for cancer staging, prediction of recurrence and prognosis, and treatment selection. Metabolic profiles, which are affected by many physiological and pathological processes, may provide further insight into the metabolic consequences of this severe liver disease. Small-molecule metabolites have an important role in biological systems and represent attractive candidates to understand HCC phenotypes. The power of metabolomics allows an unparalleled opportunity to query the molecular mechanisms of HCC. This technique-driven review aims to demystify the metabolomics pathway, while also illustrating the potential of this technique, with recent examples of its application in

show abstract

Metabolomics study of alcohol-induced liver injury and hepatocellular carcinoma xenografts in mice

Cited by 52 publications

References 45 publications

Potential serum biomarkers from a metabolomics study of autism

Potential serum biomarkers from a metabolomics study of autism

Serum Metabolic Profiling of Advanced Cirrhosis Based on HCV

Power of metabolomics in diagnosis and biomarker discovery of hepatocellular carcinoma

Contact Info

Product

Resources

About